Well, that really depends on the kind of product we're talking about. On Tuesday we heard from a witness who said that as we move toward more precision medicine, everything will become a rare disease, right? Every version of diabetes, all the different genetic variations, and so on will require different products, so I think we need to be careful about assigning blanket strategies.
One thing UBC has done in their access licensing provisions is establish basic principles that make sense. These are publicly funded discoveries, and their principles essentially state that they should be accessible and affordable to people who need them. Individual products will still require specific strategies, and for some products there will be a competitive market, but perhaps for others there won't be. What we need to get right is that there should be, at the very least at the institutional level, a set of principles that says we are paying for this discovery, and it's incumbent on us, as an institution, to ensure that there is affordable access to it and it's available to the patients who need it.